Amit M Oza

发表

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Ignace Vergote, Christian Marth, Sven Mahner, 2016, The New England journal of medicine.

The statins as anticancer agents.

Kelvin K. W. Chan, A. Oza, L. Siu, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 3 trial of bevacizumab in ovarian cancer.

Jacobus Pfisterer, Jalid Sehouli, Rainer Kimmig, 2011, The New England journal of medicine.

Outcomes and endpoints in cancer trials: bridging the divide.

Katherine Karakasis, Deborah Collyar, Ian F Tannock, 2015, The Lancet. Oncology.

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses

Igor Jurisica, Chiara Pastrello, Katherine Karakasis, 2019, International Journal of Gynecologic Cancer.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Katherine Karakasis, A. Oza, Michelle K Wilson, 2015, The Lancet. Oncology.

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Laura Vidal, Ruth Plummer, Ian Judson, 2009, Clinical Cancer Research.

Clinical development of P glycoprotein modulators in oncology.

A. Oza, Amit M Oza, 2002, Novartis Foundation symposium.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Jacobus Pfisterer, Gordon C Jayson, Michael Quinn, 2015, The Lancet. Oncology.